The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Woodham, Andrew W ^a   da Silva, Diane M ^b,c   Skeate, Joseph G ^a   Raff, Adam B ^a   Ambroso, Mark R ^a   Brand, Heike E ^c   Isas, J Mario ^a   Langen, Ralf ^a   Kast, W Martin ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; LIPOCORTIN 2; PROTEIN ANTIBODY; PROTEIN L2; PROTEIN S100A10; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; TETRAMER; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ELECTRON SPIN RESONANCE; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOPRECIPITATION; MUTATIONAL ANALYSIS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SUBUNIT; VIRUS PARTICLE;

AMINO ACID SEQUENCE; ANNEXIN A2; CAPSID PROTEINS; EPITHELIAL CELLS; EPITOPES; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; S100 PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84865156591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043519     Document Type: Article

References (79)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. ((1999)) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:: 12--19.
2. Faridi R, Zahra A, Khan K, Idrees M, ((2011)) Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J 8:: 269--277.
3. Bosch F, Manos M, Munoz N, Sherman M, Jansen A, et al. ((1995)) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on servical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:: 796--802.
4. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, et al. ((1997)) Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:: 2449--2456.
5. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, et al. ((1999)) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:: 5810--5822.
6. Richards RM, Lowry LD, Schiller JT, Day PM, ((2006)) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103:: 1522--1527.
7. Cumming S, Chuem-In T, Milligan S, Graham SV, ((2008)) Human Papillomavirus type 16 late gene expression is regulated by cellular RNA processing factors in response to epithelial differentiation. Biochem Soc Trans 36:: 522--524.
8. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, ((1992)) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:: 12180--12184.
9. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, et al. ((2008)) Arrangement of L2 within the papillomavirus capsid. J Virol 82:: 5190--5197.
10. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT, ((2005)) Maturation of papillomavirus capsids. J Virol 79:: 2839--2846.
11. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M, ((2001)) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:: 1565--1570.
12. Bienkowska-Haba M, Patel HD, Sapp M, ((2009)) Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog 5:: e1000524.
13. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, et al. ((2008)) Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS ONE 3:: e3313.
14. Surviladze Z, Dziduszko A, Ozbun MA, ((2012)) Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 8:: e1002519.
15. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, et al. ((2012)) Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog 8:: e1002657.
16. Fausch SC, Da Silva DM, Kast WM, ((2003)) Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 63:: 3478--3482.
17. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, et al. ((2011)) Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem 286:: 2617--2624.
18. Pereira R, Hitzeroth, II, Rybicki EP, ((2009)) Insights into the role and function of L2, the minor capsid protein of papillomaviruses. Arch Virol 154:: 187--197.
19. Richards RM, Lowy DR, Schiller JT, Day PM, ((2006)) Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A 103:: 1522--1527.
20. Day PM, Lowry DR, Schiller JT, ((2008)) Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J Virol 82:: 12565--12568.
21. Selinka H, Florin L, Patel HD, Freitag K, Schmidtke M, et al. ((2007)) Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J Virol 81:: 10970--10980.
22. Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, et al. ((2007)) A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine 25:: 2001--2010.
23. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, ((1999)) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73:: 6188--6190.
24. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, et al. ((2007)) Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:: 266--272.
25. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C, ((2011)) Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS ONE 6:: e16405.
26. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. ((2007)) A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 81:: 13927--13931.
27. Embers ME, Budgeon LR, Culp TD, Reed CA, Pickel MD, et al. ((2004)) Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. Vaccine 22:: 670--680.
28. Kawana Y, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, et al. ((2001)) Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol 75:: 2331--2336.
29. Yang R, Day PM, Yutzy WH, Lin KY, Hung CF, et al. ((2003)) Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection. J Virol 77:: 3531--3541.
30. Rawls WE, Tompkins WA, Figueroa ME, Melnick JL, ((1968)) Herpesvirus type 2: association with carcinoma of the cervix. Science 161:: 1255--1256.
31. Simon JW, ((1976)) The association of Herpes simplex virus and cervical cancer: a review. Gynecol Oncol 4:: 108--116.
32. Park M, Kitchener HC, Macnab JC, ((1983)) Detection of herpes simplex virus type-2 DNA restriction fragments in human cervical carcinoma tissue. EMBO J 2:: 1029--1034.
33. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, et al. ((2008)) Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 82:: 9337--9344.
34. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, et al. ((2004)) Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med 200:: 1337--1346.
35. Waisman DM, ((1995)) Annexin II tetramer: structure and function. Mol Cell Biochem 149/150:: 301--322.
36. Rescher U, Gerke V, ((2008)) S100A10/p11: family, friends and functions. Pflugers Archiv 455:: 575--582.
37. Pena-Alonso E, Rodrigo JP, Parra IC, Pedrero JM, Meana MV, et al. ((2008)) Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 263:: 89--98.
38. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, et al. ((2006)) Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 103:: 1516--1521.
39. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA, ((2004)) An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem 279:: 43411--43418.
40. Fligge C, Schafer F, Selinka HC, Sapp C, Sapp M, ((2001)) DNA-induced structural changes in the papillomavirus capsid. J Virol 75:: 7727--7731.
41. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M, ((2003)) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77:: 12961--12967.
42. Volpers C, Schirmacher P, Streeck RE, Sapp M, ((1994)) Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 200:: 504--512.
43. Longhi S, Belle V, Fournel A, Guigliarelli B, Carriere F, ((2011)) Probing structural transitions in both structured and disordered proteins using site-directed spin-labeling EPR spectroscopy. J Pept Sci 17:: 315--328.
44. Holmgren SC, Patterson NA, Ozbun MA, Lambert PF, ((2005)) The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol 79:: 3938--3948.
45. Puisieux A, Ji J, Ozturk M, ((1996)) Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochem J 313 (Pt 1):: 51--55.
46. He KL, Deora AB, Xiong H, Ling Q, Weksler BB, et al. ((2008)) Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11. J Biol Chem 283:: 19192--19200.
47. Mercer J, Schelhaas M, Helenius A, ((2010)) Virus entry by endocytosis. Annu Rev Biochem 79:: 803--833.
48. Sieczkarski SB, Whittaker GR, ((2005)) Viral entry. Curr Top Microbiol Immunol 285:: 1--23.
49. Day PM, Lowy DR, Schiller JT, ((2003)) Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307:: 1--11.
50. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, et al. ((2008)) Clathrin- and caveolin-independent entry of human papillomavirus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS ONE 3:: e3313.
51. Zhang J, Guo B, Zhang Y, Cao J, Chen T, ((2010)) Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion. Saudi Med J 31:: 374--381.
52. Dreier R, Schmid KW, Gerke V, Riehemann K, ((1998)) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem Cell Biol 110:: 137--148.
53. Gerke V, Creutz CE, Moss SE, ((2005)) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6:: 449--461.
54. Wright JF, Kurosky A, Wasi S, ((1994)) An endothelial cell-surface form of annexin II binds human cytomegalovirus. Biochem Biophys Res Commun 198:: 983--989.
55. Raynor CM, Wright JF, Waisman DM, Pryzdial EL, ((1999)) Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes. Biochemistry 38:: 5089--5095.
56. Malhotra R, Ward M, Bright H, Priest R, Foster MR, et al. ((2003)) Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 5:: 123--133.
57. Yang SL, Chou YT, Wu CN, Ho MS, ((2011)) Annexin II Binds to Capsid Protein VP1 of Enterovirus 71 and Enhances Viral Infectivity. J Virol 85:: 11809--11820.
58. Shao C, Zhang F, Kemp MM, Linhardt RJ, Waisman DM, et al. ((2006)) Crystallographic analysis of calcium-dependent heparin binding to annexin A2. J Biol Chem 281:: 31689--31695.
59. Compton T, ((2004)) Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 14:: 5--8.
60. Duncan CJ, Sattentau QJ, ((2011)) Viral determinants of HIV-1 macrophage tropism. Viruses 3:: 2255--2279.
61. Schiller JT, Day PM, Kines RC, ((2010)) Current understanding of the mechanism of HPV infection. Gynecol Oncol 118:: S12--17.
62. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT, ((2008)) Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 82:: 4638--4646.
63. Mitra SK, Schlaepfer DD, ((2006)) Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18:: 516--523.
64. Serrels B, Frame MC, ((2012)) FAK and talin: who is taking whom to the integrin engagement party? J Cell Biol 196:: 185--187.
65. Abban CY, Meneses PI, ((2010)) Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 403:: 1--16.
66. Hayes MJ, Shao D, Grieve A, Levine T, Bailly M, et al. ((2009)) Annexin A2 at the interface between F-actin and membranes enriched in phosphatidylinositol 4,5,-bisphosphate. Biochim Biophys Acta 1793:: 1086--1095.
67. Willis SH, Rux AH, Peng C, Whitbeck JC, Nicola AV, et al. ((1998)) Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J Virol 72:: 5937--5947.
68. Moreau T, Baranger K, Dade S, Dallet-Choisy S, Guyot N, et al. ((2008)) Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 90:: 284--295.
69. Williams SE, Brown TI, Roghanian A, Sallenave JM, ((2006)) SLPI and elafin: one glove, many fingers. Clin Sci 110:: 21--35.
70. Moriyama A, Shimoya K, Ogata I, Kimura T, Nakamura T, et al. ((1999)) Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle. Mol Hum Reprod 5:: 656--661.
71. Kramps JA, Franken C, Dijkman JH, ((1984)) ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis 129:: 959--963.
72. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, et al. ((1995)) Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 96:: 456--464.
73. Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, et al. ((1991)) Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest 87:: 482--488.
74. Cordes C, Hasler R, Werner C, Gorogh T, Rocken C, et al. ((2011)) The level of secretory leukocyte protease inhibitor is decreased in metastatic head and neck squamous cell carcinoma. Int J Oncol 39:: 185--191.
75. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. ((1988)) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:: 761--771.
76. Langen R, Isas JM, Luecke H, Haigler HT, Hubbell WL, ((1998)) Membrane-mediated assembly of annexins studied by site-directed spin labeling. J Biol Chem 273:: 22453--22457.
77. Rety S, Sopkova J, Renouard M, Osterloh D, Gerke V, et al. ((1999)) The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat Struct Biol 6:: 89--95.
78. Buck CB, Thompson CD (2007) Production of papillomavirus-based gene transfer vectors. Current protocols in cell biology/editorial board, Juan S Bonifacino [et al] Chapter 26: Unit 26 21.
79. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT, ((1992)) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:: 12180--12184.